JP2024527362A5 - - Google Patents
Info
- Publication number
- JP2024527362A5 JP2024527362A5 JP2024500476A JP2024500476A JP2024527362A5 JP 2024527362 A5 JP2024527362 A5 JP 2024527362A5 JP 2024500476 A JP2024500476 A JP 2024500476A JP 2024500476 A JP2024500476 A JP 2024500476A JP 2024527362 A5 JP2024527362 A5 JP 2024527362A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- sequence
- optionally
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220108P | 2021-07-09 | 2021-07-09 | |
| US63/220,108 | 2021-07-09 | ||
| PCT/US2022/073529 WO2023283615A1 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527362A JP2024527362A (ja) | 2024-07-24 |
| JP2024527362A5 true JP2024527362A5 (OSRAM) | 2025-07-17 |
Family
ID=84802089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500476A Pending JP2024527362A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240318177A1 (OSRAM) |
| EP (1) | EP4366783A4 (OSRAM) |
| JP (1) | JP2024527362A (OSRAM) |
| KR (1) | KR20240035826A (OSRAM) |
| CN (1) | CN118591391A (OSRAM) |
| AU (1) | AU2022306692A1 (OSRAM) |
| CA (1) | CA3226307A1 (OSRAM) |
| IL (1) | IL309935A (OSRAM) |
| MX (1) | MX2024000493A (OSRAM) |
| WO (1) | WO2023283615A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| CA3137715A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| EP2203173B1 (en) * | 2007-10-26 | 2015-12-23 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| CN110382695A (zh) * | 2016-11-28 | 2019-10-25 | 得克萨斯州大学系统董事会 | 通过crispr/cpf1介导的基因编辑来预防肌营养不良 |
| JP7611825B2 (ja) * | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| CA3137715A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| EP4023673A4 (en) * | 2019-10-10 | 2023-03-15 | Suzhou Qin Pharmaceuticals Co., Ltd. | ANTI-BCMA HUMANIZED MONOCLONAL ANTIBODY WITH HUMAN-MONKEY CROSS-REACTIVITY |
| US20230285586A1 (en) * | 2020-07-23 | 2023-09-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
-
2022
- 2022-07-08 WO PCT/US2022/073529 patent/WO2023283615A1/en not_active Ceased
- 2022-07-08 EP EP22838587.8A patent/EP4366783A4/en active Pending
- 2022-07-08 KR KR1020247004340A patent/KR20240035826A/ko active Pending
- 2022-07-08 JP JP2024500476A patent/JP2024527362A/ja active Pending
- 2022-07-08 US US18/577,378 patent/US20240318177A1/en active Pending
- 2022-07-08 IL IL309935A patent/IL309935A/en unknown
- 2022-07-08 MX MX2024000493A patent/MX2024000493A/es unknown
- 2022-07-08 AU AU2022306692A patent/AU2022306692A1/en active Pending
- 2022-07-08 CN CN202280060812.8A patent/CN118591391A/zh active Pending
- 2022-07-08 CA CA3226307A patent/CA3226307A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525611A5 (OSRAM) | ||
| JP2024525610A5 (OSRAM) | ||
| JP2024525613A5 (OSRAM) | ||
| JP2024525612A5 (OSRAM) | ||
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (OSRAM) | ||
| JP2023535073A5 (OSRAM) | ||
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20250099603A9 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| KR20240035825A (ko) | 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제 | |
| JP2023509793A5 (OSRAM) | ||
| JP2024540199A5 (OSRAM) | ||
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| JP2024524222A5 (OSRAM) | ||
| JP2024534488A5 (OSRAM) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| JP2023549537A5 (OSRAM) |